Technical Analysis for RYTM - Rhythm Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Resistance | Bearish | -0.56% | |
| Fell Below 20 DMA | Bearish | -0.56% | |
| Multiple of Ten Bearish | Other | -0.56% | |
| Outside Day | Range Expansion | -0.56% | |
| Gapped Up | Strength | -0.56% | |
| 50 DMA Resistance | Bearish | -2.48% | |
| Calm After Storm | Range Contraction | -2.48% | |
| NR7 | Range Contraction | -2.48% | |
| Narrow Range Bar | Range Contraction | -2.48% | |
| Multiple of Ten Bullish | Other | -2.48% |
| Alert | Time |
|---|---|
| Fell Below Previous Day's Low | about 3 hours ago |
| Down 2 % | about 23 hours ago |
| Fell Below 20 DMA | about 23 hours ago |
| Outside Day | about 23 hours ago |
| Fell Below Previous Day's Low | about 23 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/07/2024
Rhythm Pharmaceuticals, Inc. Description
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity. Setmelanotide serves as replacement therapy for the treatment of melanocortin-4, or MC4, pathway deficiencies. MC4 pathway deficiencies result in the disruption of satiety signals and energy homeostasis in the body, which, in turn, leads to intense feelings of hunger and to obesity. The Company also focused on obesity related to six single gene-related, or monogenic, MC4 pathway deficiencies pro-opiomelanocortin, or POMC, leptin receptor, or LepR, Bardet-Biedl syndrome, Alstrom syndrome, POMC heterozygous, and POMC epigenetic disorders.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Obesity Peptides Peptide Hormones Metabolic Disorders Monogenic Genetic Disorder Leptin Melanocortin
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 52.57 |
| 52 Week Low | 15.5001 |
| Average Volume | 574,943 |
| 200-Day Moving Average | 35.29 |
| 50-Day Moving Average | 40.36 |
| 20-Day Moving Average | 39.80 |
| 10-Day Moving Average | 40.47 |
| Average True Range | 2.16 |
| RSI (14) | 47.64 |
| ADX | 13.03 |
| +DI | 23.35 |
| -DI | 21.47 |
| Chandelier Exit (Long, 3 ATRs) | 37.88 |
| Chandelier Exit (Short, 3 ATRs) | 43.07 |
| Upper Bollinger Bands | 43.05 |
| Lower Bollinger Band | 36.55 |
| Percent B (%b) | 0.47 |
| BandWidth | 16.32 |
| MACD Line | -0.20 |
| MACD Signal Line | -0.21 |
| MACD Histogram | 0.011 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 43.43 | ||||
| Resistance 3 (R3) | 43.76 | 42.83 | 42.79 | ||
| Resistance 2 (R2) | 42.83 | 41.85 | 42.66 | 42.57 | |
| Resistance 1 (R1) | 41.21 | 41.25 | 40.75 | 40.88 | 42.36 |
| Pivot Point | 40.28 | 40.28 | 40.04 | 40.11 | 40.28 |
| Support 1 (S1) | 38.66 | 39.30 | 38.20 | 38.33 | 36.84 |
| Support 2 (S2) | 37.73 | 38.70 | 37.56 | 36.63 | |
| Support 3 (S3) | 36.11 | 37.73 | 36.41 | ||
| Support 4 (S4) | 35.78 |
